Amyris, Inc. plans to acquire Oobli Inc., bringing together the California biomanufacturing company's fermentation capacity and commercial reach with Oobli's platform for fermentation-derived sweet proteins. Amyris is based in Emeryville, California; Oobli is based in Davis, California. The companies announced the agreement.
The acquisition is intended to combine Amyris's scientific capabilities and manufacturing depth with Oobli's protein fermentation expertise. Amyris said the move follows its expansion earlier this year of manufacturing capacity at its advanced fermentation facility in Barra Bonita, Brazil. The company described the deal as a strategic commercial and technology expansion that would accelerate its presence in protein- and peptide-based solutions across end markets.
Sweet-protein platform
Oobli's commercial portfolio is expected to be the first to benefit from the combined platform. For the past decade, Oobli has been refining a fermentation process to produce sweet proteins that occur naturally in rare fruits and berries near the equator. According to the company, these proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein. Oobli says this allows them to deliver sweetness without gut disruption or blood sugar spikes.
The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit sweet proteins, known scientifically as brazzein, monellin and thaumatin, respectively. Oobli says the ingredients have FDA GRAS status as an ingredient and are FEMA GRAS-affirmed for use as a natural flavor. The company is targeting sugar reduction across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery, as consumer interest in metabolic health grows.
Leadership view
Amyris CEO Kathy Fortmann said Oobli offers a commercial and technology platform that complements Amyris's own. She said Amyris aims to bring commercial scale and resources to accelerate what she described as a sweet revolution. Combining Oobli's protein expertise with Amyris's strain engineering, manufacturing scale and commercial capabilities could broaden the combined company's work in food and beverage, personal care, flavor and fragrance, agriculture and other markets, Fortmann said.
Oobli CEO Ali Wing said the transaction would give Oobli the scale and resources to pursue its ambition of making sweet proteins a global standard in sweetness solutions. Wing said Oobli had long believed there was a better way to deliver the sweet taste consumers want without trade-offs to health and the environment, and pointed to the breakthroughs the company has achieved.
Fortmann added that biomanufactured solutions succeed when they align with consumer demand and market needs, and said Oobli's platform does that by giving brands a way to address sweet taste, sugar reduction and clean label at the same time. Amyris said it looks forward to welcoming Oobli's team and realizing synergies between the two platforms.
Commercial continuity
The acquisition is expected to close in the coming weeks. Amyris said all existing customer commitments and brand partnerships will continue to be honored without interruption as Oobli's sweet-protein portfolio expands within Amyris.
